Focus:
Deal News
-
13 February 2020
OSE Immunotherapeutics and MAbSilico enter AI partnership
French biotechnology firm OSE Immunotherapeutics has signed a three-year agreement with technology start-up MAbSilico to leverage artificial intelligence (AI) technology for the development of monoclonal antibody drugs.
-
13 February 2020
Dr Reddy’s to buy some Wockhardt generics units for $259m
Dr Reddy’s Laboratories has signed a definitive agreement to acquire certain divisions of Wockhardt’s branded generics business for a consideration of $259.4m (INR18.5bn).
-
12 February 2020
Bayer to transfer research unit in Berlin to Nuvisan
Healthcare company Bayer has signed a definitive agreement to transfer the majority of its small molecule research unit in Berlin, Germany to Nuvisan.
-
12 February 2020
J&J partners HHS to speed-up coronavirus vaccine development
Johnson & Johnson (J&J) unit Janssen Pharmaceutical has partnered with the US Department of Health & Human Services (HHS) to speed-up the development of its investigational vaccine candidate against the...
-
11 February 2020
Luye Pharma grants certain rights for Seroquel to Cipla Medpro
Luye Pharma Group has granted Cipla Medpro South Africa exclusive rights to distribute and market antipsychotic drug Seroquel in South Africa, Namibia and Botswana.
-
10 February 2020
Applied DNA and Takis Biotech partner on coronavirus vaccine
Applied DNA Sciences has extended its partnership with Takis Biotech to include the development of a vaccine for 2019-nCoV coronavirus.
-
10 February 2020
Zealand Pharma makes stalking horse bid for Valeritas
Danish biotechnology firm, Zealand Pharma has made a bid to acquire Valeritas, a medical technology company focused on diabetes therapeutics.
-
7 February 2020
Assertio to divest US rights to Nucynta to Collegium for $375m
Assertio Therapeutics has signed a definitive agreement to sell its Nucynta franchise to Collegium Pharmaceutical for a cash consideration of $375m.
-
6 February 2020
Aimmune secures $200m funding from Nestlé Health Science
US-based biopharmaceutical company Aimmune Therapeutics is set to receive $200m in equity investment from Nestlé Health Science.
-
5 February 2020
Bridge Biotherapeutics in-licenses Konkuk University’s back eye disorder drug
South Korea-based Bridge Biotherapeutics has acquired an early stage back eye disorder drug from Konkuk University for a total of $8.4m (10bn KRW).
Close
Close
Close
Go Top